Attached files
| file | filename |
|---|---|
| 8-K - CURRENT REPORT - Avid Bioservices, Inc. | pphm_8k.htm |
| EX-10.29 - AT MARKET ISSUANCE SALES AGREEMENT - Avid Bioservices, Inc. | pphm_8k-ex1029.htm |
| EX-5.1 - OPINION - Avid Bioservices, Inc. | pphm_8k-ex0501.htm |
| EX-8.1 - OPINION - Avid Bioservices, Inc. | pphm_8k-ex0801.htm |
| EX-10.28 - AT MARKET ISSUANCE SALES AGREEMENT - Avid Bioservices, Inc. | pphm_8k-ex1028.htm |
Exhibit 12.1
Peregrine Pharmaceuticals, Inc.
Statement Regarding Computation of Ratios
| Fiscal Year Ended April 30, | Nine Months Ended January 31, | |||||||||||||||||||||||
| 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | |||||||||||||||||||
| (in thousands) | ||||||||||||||||||||||||
| Earnings: | ||||||||||||||||||||||||
| Pretax loss from operations | $ | (16,524 | ) | $ | (14,494 | ) | $ | (34,151 | ) | $ | (42,119 | ) | $ | (29,780 | ) | $ | (25,114 | ) | ||||||
| Add: fixed charges | 972 | 1,478 | 1,108 | 638 | 2,219 | 319 | ||||||||||||||||||
| Total earnings available for fixed charges | $ | (15,552 | ) | $ | (13,016 | ) | $ | (33,043 | ) | $ | (41,481 | ) | $ | (27,561 | ) | $ | (24,795 | ) | ||||||
| Fixed Charges: | ||||||||||||||||||||||||
| Interest expense | 223 | 518 | 281 | 55 | 46 | 1 | ||||||||||||||||||
| Amortization of discount on notes payable and debt issuance costs | 185 | 430 | 235 | 33 | – | – | ||||||||||||||||||
| Loss on extinguishment of debt | – | – | – | – | 1,696 | – | ||||||||||||||||||
| Interest component of rent expense (1) | 564 | 530 | 592 | 550 | 477 | 318 | ||||||||||||||||||
| Total Fixed Charges | $ | 972 | $ | 1,478 | $ | 1,108 | $ | 638 | $ | 2,219 | $ | 319 | ||||||||||||
| Deficiency of earnings available to cover combined fixed charges and preferred stock dividends | $ | (16,524 | ) | $ | (14,494 | ) | $ | (34,151 | ) | $ | (42,119 | ) | $ | (29,780 | ) | $ | (25,114 | ) | ||||||
___________________
(1) Represents the portion of rental expense from operating leases that is estimated by us to be representative of interest.